Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients With Relapsed or Refractory Multiple Myeloma

NCT03287804 is registered in ClinicalTrials.gov with Autolus Limited as lead sponsor.

NCT NCT03287804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03287804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Autolus Limited
Phase
Phase 1/2
Overall status
Terminated
Start date
May 5, 2017
Completion date
September 5, 2019
Enrollment
12 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma